Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Ad5-nCoV in Healthy Adults
NCT04313127Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Mar 2020
- Primary completion
- Jan 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Safety indexes of adverse reactions. Started Mar 2020; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04313127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313127.